CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 192309-192593 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"T86353","span":{"begin":0,"end":284},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"We have previously reported Th1 and Th2 cytokine alterations associated with several clinical entities that had overlapping disease manifestations affecting the mucosal-associated lymphoid tissues (MALT), of the GI tract (GALT), skin (SALT), nasal (NALT) and bronchial tissues (BALT)."}

    Epistemic_Statements

    {"project":"Epistemic_Statements","denotations":[{"id":"T342","span":{"begin":0,"end":284},"obj":"Epistemic_statement"}],"text":"We have previously reported Th1 and Th2 cytokine alterations associated with several clinical entities that had overlapping disease manifestations affecting the mucosal-associated lymphoid tissues (MALT), of the GI tract (GALT), skin (SALT), nasal (NALT) and bronchial tissues (BALT)."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T447","span":{"begin":0,"end":284},"obj":"Sentence"}],"text":"We have previously reported Th1 and Th2 cytokine alterations associated with several clinical entities that had overlapping disease manifestations affecting the mucosal-associated lymphoid tissues (MALT), of the GI tract (GALT), skin (SALT), nasal (NALT) and bronchial tissues (BALT)."}

    CORD-19-PD-UBERON

    {"project":"CORD-19-PD-UBERON","denotations":[{"id":"T367","span":{"begin":180,"end":196},"obj":"Body_part"},{"id":"T368","span":{"begin":229,"end":233},"obj":"Body_part"}],"attributes":[{"id":"A367","pred":"uberon_id","subj":"T367","obj":"http://purl.obolibrary.org/obo/UBERON_0001744"},{"id":"A368","pred":"uberon_id","subj":"T368","obj":"http://purl.obolibrary.org/obo/UBERON_0000014"}],"text":"We have previously reported Th1 and Th2 cytokine alterations associated with several clinical entities that had overlapping disease manifestations affecting the mucosal-associated lymphoid tissues (MALT), of the GI tract (GALT), skin (SALT), nasal (NALT) and bronchial tissues (BALT)."}